- IPC GENERAL
- IPC News, IPC Partners
In April, the International Psoriasis Council (IPC) joined patient leaders, clinicians, and organizations from across North, South, and Central America for the International Federation of Psoriatic Disease Association (IFPA) Forum Americas in Bogotá, Colombia. United by a shared commitment to advancing access to care and promoting equity for people living with psoriasis, IPC was proud to collaborate with IFPA throughout the multi-day event.
The Forum opened on Friday, April 4, with welcoming remarks from IFPA President Ingvar Ingvarsson. IPC CEO Christy Langan joined Ingvarsson to open the first session of the day with an impactful discussion on the importance of cross-border collaboration in driving progress and improving care for patients worldwide.
On Saturday, April 5, IPC and IFPA co-hosted a morning session that brought together advocates and healthcare professionals from across the region to explore shared challenges and opportunities in psoriasis care. During this session, Langan presented IPC’s 2025 priorities, including expanding access to systemic therapies, supporting the development of treatment guidelines, and encouraging the adoption of IPC’s updated disease severity criteria. The session closed with a call to action: deepen collaboration, get involved, and ensure the patient’s voice continues to shape the future of care.
IPC also convened its attending Councilors, Fellows, and Board Members from the Americas to discuss regional strategies for closing treatment gaps and strengthening national care frameworks. Conversations focused on practical needs, such as harmonized treatment guidelines and broader awareness of IPC’s severity classification, while emphasizing the essential role of local leadership and patient advocacy. Attendees received a draft toolkit of IPC’s updated severity classification materials and committed to piloting them in local training sessions. As 2025 IPC Fellow Ralph Vighi da Rosa reflected, “This event gave me fresh perspectives on advancing psoriatic disease care across Latin America and beyond. I forged meaningful connections with peers from multiple countries—a true eye‑opener.”
“The IFPA Forum Americas allowed us to listen, contribute, and plan together,” said Langan. “We are committed to deepening our engagement in Latin America and ensuring the patient voice continues to shape the future of psoriasis care.”
A big thank‑you to IFPA for hosting a truly collaborative Forum—and to everyone from the IPC community whose ideas will help transform psoriasis care across the Americas.
